 NESS ZIONA, Israel LAUSANNE, Switzerland--BUSINESS WIRE--Sol-Gel Technologies, Ltd. NASDAQ: SLGL, a clinical-stage dermatology company, and Galderma, the worlds largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY and TWYNEO in the United States. Under these agreements, Galderma has an exclusive license to commercialize Sol-Gels most advanced investigational drug products using Sol-Gels 